Skip to content

U-100 unit conversion

Testagen calculator

Convert mass and volume to U-100 units. No dose is selected.

These are example numbers so you can see the math. Try yours. Change them to match the vial in your hand.

5U-100 units · 0.05 mL

50 mcg per unit · 5000 mcg/mL

How the calculator works, sources and review dates

Testagen math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 10 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.

Editorial review 2026-10-10. source-curated; clinician review pending.

Units chart for listed Testagen sizes

This card has no units chart until a milligram size is listed.

What is Testagen?

Other names in the library: Testagen. Evidence describes the named substance, not a quality certification or equivalence assessment of commercial stock. Listed sizes: no listed milligram sizes in the vendor file. A seller title is a listing. It does not prove the vial matches a paper.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Regulatory context

Regulatory context; not efficacy evidence

No matched controlled patient-efficacy study of this exact supplier preparation was verified.

Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.

Nonresponse. Nonresponse frequency not established in this excerpt.

Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.

Limits. Mechanistic or cellular bioregulator research cannot establish a clinical benefit for this supplier product.

Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Lab or animal research

Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA.

HeLa cells and deoxyribooligonucleotide/DNA assays; no treated patients.

Reported findings. Labelled-peptide nuclear/cytoplasmic fluorescence and sequence-dependent nucleic-acid interactions were reported.

Nonresponse. No testosterone, fertility or patient benefit outcome was measured.

Harms. Human adverse outcomes or safety were not measured.

Limits. FITC labelling, fluorescence quenching and laboratory exposure limit inference about intact commercial peptide uptake. An inconsistent discussion sentence involving alanine does not override the KEDG identity stated in methods. Mechanistic interactions are not evidence of clinical androgen effects.

Preparation: Experimental Lys-Glu-Asp-Gly (KEDG); FITC-labelled peptide for HeLa exposure plus intact-peptide cell-free nucleic-acid assays. Route: Cell culture and cell-free incubation; no therapeutic delivery route.

Read original source ↗

Editorial review 2026-10-10. Clinician review pending.

Clinical observation

Efficacy of testosterone synthesis inductor application Testagen in androgenic deficiency in patients with chronic abacterial prostatitis

36 men aged 38–49 with chronic abacterial prostatitis IIIA and low testosterone; 20 add-on recipients versus 16 standard-treatment recipients.

Reported findings. Authors reported symptom/uroflow and testosterone improvements during 30-day treatment, with larger reported changes in the add-on group.

Nonresponse. Both groups improved; testosterone significance annotations compare with baseline rather than establishing a between-group treatment effect.

Harms. Adverse-event outcomes and systematic harms assessment were not reported; absence of reporting is not demonstrated safety.

Limits. Randomization/blinding were not described; tamsulosin and rectal diclofenac were co-interventions. The table supplies one baseline testosterone value of 7.1 nmol/L and post-treatment values of 7.5 standard versus 9.8 add-on; these are not group-specific baseline changes or a verified causal effect. Baseline leukocyte count is 20.8 in body versus 28.2 in the table; inconsistent time-to-peak wording also limits interpretation. This oral complex is not verified as the injectable catalog KEDG preparation. ClinicalTrials.gov NCT02733133 concerns topical Testagen TDS 5% testosterone, an unrelated compound; it must not support this product.

Preparation: FirmaVita oral food-supplement capsules containing AKS-S peptide complex listing lysine, glutamate, aspartate and glycine; purified KEDG identity/equivalence is unverified. Route: Oral supplement added to standard treatment; not injectable purified Testagen.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Compounding

not established. Legal compounding eligibility is not established here. Sale or a supplement label does not establish eligibility.

Research

source limited. No matched controlled patient-efficacy study of this exact supplier preparation was verified.

Sport

unknown. Not individually verified against current sport rules. Check the exact ingredients with your sport authority.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule.

Half-life on file: no single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.

Risks and mix-ups already on the record

  • Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
  • No complete contraindication list is established for this exact preparation. Review pregnancy, allergies and existing conditions with a clinician.
  • No complete interaction study for this exact preparation is verified. Ingredient combinations are not presumed compatible.

People using PepBear often log: Exact product identity, formulation, dated label and any clinician-directed observations. Record symptoms and changes alongside other medicines, sleep and activity; observations do not establish causation.

Sources

  1. Regulatory context; not efficacy evidence · checked 2026-10-09

Questions people ask

Is Testagen FDA-approved?

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Does PepBear pick an amount of Testagen?

The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.

How many units is a listed Testagen vial after you add water?

Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.

Why flag amounts under 5 units?

A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.

Related cards

Discuss the evidence and unresolved identity or safety questions with a licensed clinician. This entry provides no treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.